Skip to Content

Rule

New Animal Drugs; Withdrawal of Approval of New Animal Drug Applications

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notification of withdrawal.

SUMMARY:

The Food and Drug Administration (FDA) is withdrawing approval of 11 new animal drug applications (NADAs) and 4 abbreviated new animal drug applications (ANADAs). These withdrawals of approval of NADAs and ANADAs for antimicrobial drugs of importance to human medicine that are administered to food-producing animals in medicated feed are being made because the products are no longer being manufactured or marketed. These actions are consistent with the FDA Center for Veterinary Medicine's initiative for the Judicious Use of Antimicrobials.

DATES:

Withdrawal of approval is effective December 30, 2016.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Sujaya Dessai, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-402-5761, sujaya.dessai@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

FDA is withdrawing approval of 11 NADAs and 4 ANADAs. These applications were identified as being affected by guidance for industry (GFI) #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions With GFI #209,” December 2013 (http://www.fda.gov/​downloads/​AnimalVeterinary/​GuidanceComplianceEnforcement/​GuidanceforIndustry/​UCM299624.pdf). Their withdrawal of approval is consistent with the FDA Center for Veterinary Medicine's initiative for the Judicious Use of Antimicrobials.

Approval of the following applications for new animal drugs administered in medicated feed is being voluntarily withdrawn at the sponsors' requests because these products are no longer manufactured or marketed:

File No.Product nameSponsor
034-085LINCOMIX (lincomycin hydrochloride monohydrate) Type A Medicated ArticleZoetis Inc., 333 Portage St., Kalamazoo, MI 49007.
035-287OM-5 Premix (oleandomycin) Type A Medicated ArticlePhibro Animal Health Corp., GlenPointe Centre East, 3d Floor, 300 Frank W. Burr Blvd., Suite 21, Teaneck, NJ 07666.
046-668Penicillin G Procaine 50% Type A Medicated ArticlePhibro Animal Health Corp., GlenPointe Centre East, 3d Floor, 300 Frank W. Burr Blvd., Suite 21, Teaneck, NJ 07666.
091-668CHLORMAX-SP 500 (chlortetracycline, sulfamethazine, penicillin G procaine) Type A Medicated ArticleZoetis Inc., 333 Portage St., Kalamazoo, MI 49007.
108-116LINCOMIX (lincomycin)/NICARB (nicarbazin)Phibro Animal Health Corp., GlenPointe Centre East, 3d Floor, 300 Frank W. Burr Blvd., Suite 21, Teaneck, NJ 07666.
133-334Virginiamycin Type A Medicated ArticleZoetis Inc., 333 Portage St., Kalamazoo, MI 49007.
139-473STAFAC (virginiamycin)/STENEROL (halofuginone hydrobromide)Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.
140-340LINCOMIX (lincomycin)/STENOROL (halofuginone hydrobromide)Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.
140-443HYGROMIX 1.6 (hygromycin B) Type A Medicated ArticleZoetis Inc., 333 Portage St., Kalamazoo, MI 49007.
140-947LINCOMIX (lincomycin)/MAXIBAN (narasin and nicarbazin)Elanco US, Inc., 2500 Innovation Way, Greenfield, IN 46140.
141-090STAFAC (virginiamycin)/CLINICOX (diclazuril)Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.
200-171LINCOMIX (lincomycin)/NICARMIX (nicarbazin)Planalquimica Industrial Ltda., Rua das Magnolias nr. 2405, Jardim das Bandeiras, CEP 13053-120, Campinas, Sao Paulo, Brazil.
200-569TYLAN (tylosin)/SACOX (salinomycin)Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.
200-570TYLOVET 100 (tylosin)/BIO-COX (salinomycin)Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.
200-580TYLOVET 100 (tylosin)/SACOX (salinomycin)Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 Notice of withdrawal of approval of application (21 CFR 514.116), notice is given that approval of NADAs 034-085, 035-287, 046-668, 091-668, 108-116, 133-334, 139-473, Start Printed Page 95026140-340, 140-443, 140-947, 141-090, 200-171, 200-569, 200-570, and 200-580, and all supplements and amendments thereto, is hereby withdrawn, effective December 31, 2016.

Elsewhere in this issue of the Federal Register, FDA is amending the animal drug regulations to reflect the voluntary withdrawal of approval of these applications.

Start Signature

Dated: December 20, 2016.

Tracey H. Forfa,

Deputy Director, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 2016-31082 Filed 12-23-16; 8:45 am]

BILLING CODE 4164-01-P